Premium
P4‐259: EXCEPTIONALLY LOW RISK OF ALZHEIMER'S DEMENTIA IN APOE2 HOMOZYGOTES
Author(s) -
Reiman Eric M.,
Arboleda-Velasquez Joseph F.,
Quiroz Yakeel T.,
Huentelman Matthew J.,
Beach Thomas G.,
Farrer Lindsay A.,
Mayeux Richard,
Haines Jonathan L.,
Schellenberg Gerard D.,
Beecham Gary W.,
Montine Thomas J.,
Jun Gyungah R.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.3928
Subject(s) - apolipoprotein e , odds ratio , dementia , medicine , genotype , confidence interval , confounding , alzheimer's disease , gastroenterology , allele , cohort , case control study , cohort study , risk factor , oncology , disease , biology , genetics , gene
interval relative to baseline were -1.48 beat/min(p1⁄40.0028)and -0.66ms(p1⁄40.6561), respectively. There were no significant changes in other vital sign parameters compared with baseline. Patient’s distributions for APOE allele polymorphism were as follows: ε2/ε2-0.87%, ε3/ε3-50.43%, ε4/ε4-6.09%, ε2/ε3-9.57%, ε2/ ε4-0.87%, ε3/ε4-32.17%. The significant difference of MMSE scores before and after treatment was shown (p1⁄40.0038), especially for APOE-ε4/ε4 allele carriers and less older patients (<75 years). Conclusions: These findings support the good safety and tolerability of 10mg/day donepezil for AD patients in China. There is no correlation between with APOE genotypes and AEs, but a correlation between APOE genotypes and efficacy of donepezil.